Healthcare / BiotechnologyTaipei Exchange
$52.70
+3.95 (+8.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-31.8M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4.3%
↓Gross Margin
42.4%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.8%
FCF CAGR
—
FCF margin
27.5%
FCF / Net income
-1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $611.4M · net income $-167.8M · FCF $168.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $611.4M | $611.4M | $610.2M | $491.8M | $563.0M |
| Net Income | $-167.8M | $-167.8M | $-201.8M | $-194.8M | $-269.3M |
| EBITDA | $-3.5M | $-3.5M | $-34.9M | $-24.6M | $-102.7M |
| EPS | — | — | -0.75 | -0.77 | -1.05 |
| Gross Margin | 42.4% | 42.4% | 34.6% | 45.8% | 38.3% |
| Operating Margin | -31.8% | -31.8% | -41.3% | -33.8% | -34.1% |
| Net Margin | -27.4% | -27.4% | -33.1% | -39.6% | -47.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.13 | 0.29 | 0.28 |
| Current Ratio | 16.82 | 16.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $168.4M | $168.4M | $-398.9M | $-31.8M | $-610.0M |
| Returns | |||||
| ROE | -4.3% | -4.3% | -5.0% | -7.6% | -9.9% |
| Valuation | |||||
| P/B | 3.73 | 3.73 | 5.89 | 8.58 | 6.36 |
| Growth & Yield | |||||
| Revenue Growth | 0.2% | 0.2% | 24.1% | -12.7% | — |
| EPS Growth | — | — | 2.6% | 27.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.75 → n/d
Residual
-33.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.